vs
Side-by-side financial comparison of Silence Therapeutics plc (SLN) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.
Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $8.2M, roughly 1.9× NUSCALE POWER Corp). Silence Therapeutics plc runs the higher net margin — -14.7% vs -3316.2%, a 3301.4% gap on every dollar of revenue.
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...
SLN vs SMR — Head-to-Head
Income Statement — Q1 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $8.2M |
| Net Profit | $-2.3M | $-273.3M |
| Gross Margin | 82.2% | 32.9% |
| Operating Margin | -35.6% | -6532.9% |
| Net Margin | -14.7% | -3316.2% |
| Revenue YoY | — | 1635.2% |
| Net Profit YoY | — | -1465.5% |
| EPS (diluted) | $-0.02 | $-1.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $8.2M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $13.4M | ||
| Q4 24 | — | $34.2M | ||
| Q1 24 | $15.7M | — | ||
| Q4 23 | — | $4.6M | ||
| Q3 23 | — | $7.0M | ||
| Q2 23 | — | $5.8M |
| Q3 25 | — | $-273.3M | ||
| Q2 25 | — | $-17.6M | ||
| Q1 25 | — | $-14.0M | ||
| Q4 24 | — | $-75.0M | ||
| Q1 24 | $-2.3M | — | ||
| Q4 23 | — | $-18.8M | ||
| Q3 23 | — | $-19.1M | ||
| Q2 23 | — | $-9.5M |
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 52.4% | ||
| Q4 24 | — | 91.1% | ||
| Q1 24 | 82.2% | — | ||
| Q4 23 | — | 15.8% | ||
| Q3 23 | — | 14.5% | ||
| Q2 23 | — | 0.5% |
| Q3 25 | — | -6532.9% | ||
| Q2 25 | — | -534.9% | ||
| Q1 25 | — | -264.1% | ||
| Q4 24 | — | -34.6% | ||
| Q1 24 | -35.6% | — | ||
| Q4 23 | — | -1558.2% | ||
| Q3 23 | — | -1336.9% | ||
| Q2 23 | — | -968.4% |
| Q3 25 | — | -3316.2% | ||
| Q2 25 | — | -219.0% | ||
| Q1 25 | — | -104.7% | ||
| Q4 24 | — | -219.1% | ||
| Q1 24 | -14.7% | — | ||
| Q4 23 | — | -411.3% | ||
| Q3 23 | — | -275.1% | ||
| Q2 23 | — | -164.3% |
| Q3 25 | — | $-1.85 | ||
| Q2 25 | — | $-0.13 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | $-0.77 | ||
| Q1 24 | $-0.02 | — | ||
| Q4 23 | — | $-0.25 | ||
| Q3 23 | — | $-0.26 | ||
| Q2 23 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $691.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $156.8M | $828.7M |
| Total Assets | — | $883.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $691.8M | ||
| Q2 25 | — | $420.7M | ||
| Q1 25 | — | $521.4M | ||
| Q4 24 | — | $441.6M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $120.3M | ||
| Q3 23 | — | $117.5M | ||
| Q2 23 | — | $154.4M |
| Q3 25 | — | $828.7M | ||
| Q2 25 | — | $692.9M | ||
| Q1 25 | — | $704.0M | ||
| Q4 24 | — | $618.7M | ||
| Q1 24 | $156.8M | — | ||
| Q4 23 | — | $93.5M | ||
| Q3 23 | — | $105.9M | ||
| Q2 23 | — | $110.1M |
| Q3 25 | — | $883.1M | ||
| Q2 25 | — | $606.5M | ||
| Q1 25 | — | $618.1M | ||
| Q4 24 | — | $544.7M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $224.9M | ||
| Q3 23 | — | $308.5M | ||
| Q2 23 | — | $309.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.1M | $-199.8M |
| Free Cash FlowOCF − Capex | — | $-199.9M |
| FCF MarginFCF / Revenue | — | -2425.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-199.8M | ||
| Q2 25 | — | $-33.3M | ||
| Q1 25 | — | $-22.8M | ||
| Q4 24 | — | $-26.4M | ||
| Q1 24 | $-9.1M | — | ||
| Q4 23 | — | $-73.2M | ||
| Q3 23 | — | $-27.7M | ||
| Q2 23 | — | $-39.2M |
| Q3 25 | — | $-199.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-22.9M | ||
| Q4 24 | — | $-26.5M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $-73.3M | ||
| Q3 23 | — | $-27.7M | ||
| Q2 23 | — | $-40.5M |
| Q3 25 | — | -2425.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -170.9% | ||
| Q4 24 | — | -77.3% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -1606.6% | ||
| Q3 23 | — | -399.0% | ||
| Q2 23 | — | -698.9% |
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.1% | ||
| Q1 24 | 0.0% | — | ||
| Q4 23 | — | 1.1% | ||
| Q3 23 | — | 0.8% | ||
| Q2 23 | — | 21.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SLN
Segment breakdown not available.
SMR
| Power Plant And NPM Engineering Design And Licensing Services And Fees | $8.0M | 97% |
| Other | $208.0K | 3% |
